Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 24 February, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of RPG Life Sciences Ltd

About the Company - RPG Life Sciences Ltd

RPG Life Sciences Ltd. is a Public Limited Listed company incorporated on 29/03/2007 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24232MH2007PLC169354 and registration number is 169354. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 440.16 Cr. and Equity Capital is Rs. 13.23 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
PharmaceuticalsRPG House, Mumbai Maharashtra 400030investorservices@rpgls.com
http://www.rpglifesciences.com
Management
NamePosition Held
Mr. Harsh V GoenkaChairman
Mr. Yugal SikriManaging Director
Mr. Rajat BhargavaNon Executive Director
Mr. Sachin NandgaonkarNon Executive Director
Mr. Manoj K MaheshwariIndependent Director
Mr. Narendra AmbwaniIndependent Director
Ms. Zahabiya KhorakiwalaIndependent Director
Mr. Bhaskar IyerIndependent Director
Dr. Lalit S KanodiaIndependent Director
Mr. Mahesh S GuptaIndependent Director

RPG Life Sciences Ltd. Share Price Update

Share PriceValue
Today₹1,610.75
Previous Day₹1,647.30

Basic Stock Data of RPG Life Sciences Ltd

Market Cap 2,688 Cr.
Current Price 1,626
High / Low1,740/646
Stock P/E31.7
Book Value 203
Dividend Yield0.74 %
ROCE33.2 %
ROE24.2 %
Face Value 8.00

Data Source: screener.in

Competitors of RPG Life Sciences Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Themis Medicare Ltd 2,228 Cr. 242254/10949.2 39.60.21 %19.7 %17.3 % 1.00
Nectar Lifescience Ltd 907 Cr. 40.445.7/14.4112 47.60.00 %0.18 %6.01 % 1.00
Neuland Laboratories Ltd 8,981 Cr. 7,0007,324/1,54528.3 8830.14 %20.8 %17.9 % 10.0
Pfizer Ltd 20,398 Cr. 4,4594,840/3,40740.2 7150.78 %26.2 %19.8 % 10.0
Glaxosmithkline Pharmaceuticals Ltd 38,658 Cr. 2,2822,650/1,22760.3 90.91.38 %36.4 %26.8 % 10.0
Industry Average195 Cr59.0858355.220.5%20.66%17.56%6.4

RPG Life Sciences Ltd Quarterly Results

MonthSep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Sales9710893108113116104129135131118148154
Expenses78868085879190101105101103116116
Operating Profit19211323262414283029163237
OPM %20%20%14%21%23%21%13%22%22%22%13%22%24%
Other Income0000111111222
Interest0000000000000
Depreciation4444444444444
Profit before tax1517919222111252726143035
Tax %24%25%23%30%30%29%31%28%26%26%25%26%26%
Net Profit111371416158182019102226
EPS in Rs6.747.784.188.219.528.854.5511.0112.0711.556.2613.3615.64

RPG Life Sciences Ltd Quarterly Chart

RPG Life Sciences Ltd Profit & Loss

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales193222236242279294344330376389440513550
Expenses175206224228256274306296315318353408436
Operating Profit1816121423203834607187104115
OPM %9%7%5%6%8%7%11%10%16%18%20%20%21%
Other Income1266111811-51346
Interest7733245532110
Depreciation10101111101114151616161616
Profit before tax216511223201536547392104
Tax %51%-717%18%0%0%10%34%28%20%25%30%26%
Net Profit14531122113112940516877
EPS in Rs0.512.6732.290.607.0312.708.136.5417.5424.1931.1340.9046.81
Dividend Payout %156%45%6%132%23%22%30%37%23%30%31%29%

RPG Life Sciences Ltd Profit & Loss Yearly Chart

RPG Life Sciences Ltd Growth

Compounded Sales Growth
10 Years:9%
5 Years:8%
3 Years:11%
TTM:15%
Compounded Profit Growth
10 Years:32%
5 Years:38%
3 Years:27%
TTM:31%
Stock Price CAGR
10 Years:42%
5 Years:50%
3 Years:58%
1 Year:87%
Return on Equity
10 Years:15%
5 Years:20%
3 Years:22%
Last Year:24%

RPG Life Sciences Ltd Balance Sheet

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital13131313131313131313131313
Reserves6163113112120134142147163203243294323
Borrowings546315332345543612210-0
Other Liabilities5467563949558254788588112125
Total Liabilities183206196197205247291251267303345419461
Fixed Assets109103106105109137131128123113104124128
CWIP1111229171012312542
Investments-0-0-0-0-0-0-0-0-0-0-05879
Other Assets73102899294108152106134178210211212
Total Assets183206196197205247291251267303345419461

RPG Life Sciences Ltd Reserves and Borrowings Chart

RPG Life Sciences Ltd Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 1612-6-2337154650586591
Cash from Investing Activity -8-1259-10-15-30-16-19-11-8-35-106
Cash from Financing Activity -8-0-5412-18230-26-39-10-14-17
Net Cash Flow000-0-01-1004017-32

RPG Life Sciences Ltd Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days578156614849724362542727
Inventory Days190140180149156163171136133162214203
Days Payable16122617610913510216583127132117138
Cash Conversion Cycle86-560101701107896688412491
Working Capital Days394651765450625346534733
ROCE %7%6%2%2%9%10%13%10%23%27%31%33%

RPG Life Sciences Ltd Financial Efficiency Indicators Chart

RPG Life Sciences Ltd Share Holding Pattern

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Promoters72.07%72.07%72.07%72.07%72.07%72.07%72.41%72.62%72.62%72.82%72.82%72.82%
FIIs0.01%0.01%0.00%0.02%0.20%0.12%0.15%0.08%0.25%0.38%0.33%0.46%
DIIs0.01%0.03%0.01%0.01%0.01%0.01%0.01%0.03%0.01%0.11%0.27%1.57%
Public27.91%27.89%27.92%27.90%27.72%27.80%27.43%27.27%27.11%26.70%26.58%25.15%
No. of Shareholders19,85518,70120,56423,67422,76822,82122,11520,75721,36020,83720,22621,088

RPG Life Sciences Ltd Shareholding Pattern Chart

No. of RPG Life Sciences Ltd Shareholders

RPG Life Sciences Ltd Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)
Mirae Asset Multicap Fund1652691.1822.98
Motilal Oswal S&P BSE Healthcare ETF470.070.01

RPG Life Sciences Ltd ROCE Trend

RPG Life Sciences Ltd EPS Trend

RPG Life Sciences Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
FaceValue8.008.008.008.008.00
Basic EPS (Rs.)40.9031.1324.1917.546.54
Diluted EPS (Rs.)40.9031.1324.1917.546.54
Cash EPS (Rs.)50.2740.6034.1527.4315.80
Book Value[Excl.RevalReserv]/Share (Rs.)186.00154.66130.88106.7797.05
Book Value[Incl.RevalReserv]/Share (Rs.)186.00154.66130.88106.7797.05
Dividend / Share (Rs.)12.009.607.204.002.40
Revenue From Operations / Share (Rs.)310.09266.16235.31227.10199.64
PBDIT / Share (Rs.)65.0054.0342.8436.2120.78
PBIT / Share (Rs.)55.6244.5632.8826.3211.51
PBT / Share (Rs.)55.4444.2432.4022.049.10
Net Profit / Share (Rs.)40.9031.1324.1917.546.54
PBDIT Margin (%)20.9620.2918.2015.9410.40
PBIT Margin (%)17.9316.7413.9711.585.76
PBT Margin (%)17.8716.6213.769.704.55
Net Profit Margin (%)13.1911.6910.277.723.27
Return on Networth / Equity (%)21.9820.1218.4816.426.73
Return on Capital Employeed (%)29.0527.8624.3023.6310.97
Return On Assets (%)16.1214.9313.1810.874.30
Long Term Debt / Equity (X)0.000.000.000.010.04
Total Debt / Equity (X)0.000.000.010.030.22
Asset Turnover Ratio (%)1.341.361.371.451.22
Current Ratio (X)2.572.582.211.521.25
Quick Ratio (X)1.641.551.470.950.72
Inventory Turnover Ratio (X)0.961.251.631.711.08
Dividend Payout Ratio (NP) (%)23.4723.130.0036.5036.72
Dividend Payout Ratio (CP) (%)19.1017.730.0023.3415.19
Earning Retention Ratio (%)76.5376.870.0063.5063.28
Cash Earning Retention Ratio (%)80.9082.270.0076.6684.81
Interest Coverage Ratio (X)346.74171.8389.6734.228.61
Interest Coverage Ratio (Post Tax) (X)219.19100.0051.6320.623.71
Enterprise Value (Cr.)1093.81855.55600.68287.41444.57
EV / Net Operating Revenue (X)2.131.941.540.761.35
EV / EBITDA (X)10.189.588.484.8012.94
MarketCap / Net Operating Revenue (X)2.242.101.650.751.24
Retention Ratios (%)76.5276.860.0063.4963.27
Price / BV (X)3.743.622.961.602.55
Price / Net Operating Revenue (X)2.242.101.650.751.24
EarningsYield0.050.050.060.100.02

RPG Life Sciences Ltd Profitability Ratios (%)

RPG Life Sciences Ltd Liquidity Ratios

RPG Life Sciences Ltd Liquidity Ratios (%)

RPG Life Sciences Ltd Interest Coverage Ratios (X)

RPG Life Sciences Ltd Valuation Ratios

Fair Value / Intrinsic Value of RPG Life Sciences Ltd

Fair Value: ₹1568.82

The stock is overvalued by 3.52% compared to the current price ₹1626

*Investments are subject to market risks

Strength and Weakness of RPG Life Sciences Ltd

StrengthWeakness
  1. The company has higher reserves (162.92 cr) compared to borrowings (26.00 cr), indicating strong financial stability.
  2. The company has shown consistent growth in sales (339.08 cr) and profit (38.31 cr) over the years.
  1. The stock is trading at a high valuation with an average P/B ratio of 43.77 and average Dividend Yield of 13.20%.
  2. The stock has a low average ROCE of 14.42%, which may not be favorable.
  3. The stock has a high average Working Capital Days of 50.83, which may not be favorable.
  4. The stock has a high average Cash Conversion Cycle of 80.25, which may not be favorable.

Should I Buy RPG Life Sciences Ltd Share Now?

  • Considering various financial indicators, investors might exercise caution regarding investment in RPG Life Sciences Ltd:
    1. Net Profit Margin: 13.19%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 29.05% (Industry Average ROCE: 13.85%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. Interest Coverage Ratio (Post Tax): 219.19
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    4. Quick Ratio: 1.64
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    5. ✗ Stock P/E: 32.2 (Industry average Stock P/E: 31.46)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    6. ✓ Total Debt / Equity: 0.00
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis suggests exercising caution. It's advisable to conduct further research or consult with financial experts before considering any investment.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in RPG Life Sciences Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE